Abstract
Evidence supports the current paradigm for the management of patients with recurrent or persistent ovarian carcinoma. The paradigm requires that patients be classified as platinum-sensitive or platinum-resistant. Patients who achieve a complete response with platinum-based therapy and experience at least 6 months free from recurrence should be categorized as having chemosensitive disease and should be retreated with carboplatin-based doublets. Patients who progress while receiving treatment, whose best response is stable disease, or who experience a complete response of <6 months duration should be categorized as having chemoresistant disease and should be treated with a nonplatinum single agent.
MeSH terms
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab
-
Carboplatin / therapeutic use
-
Chemotherapy, Cancer, Regional Perfusion
-
Decision Making
-
Deoxycytidine / analogs & derivatives
-
Deoxycytidine / therapeutic use
-
Disease Progression*
-
Doxorubicin / analogs & derivatives
-
Doxorubicin / therapeutic use
-
Drug Resistance, Neoplasm
-
Female
-
Gemcitabine
-
Humans
-
Neoplasm Recurrence, Local / pathology
-
Neoplasm Recurrence, Local / therapy*
-
Neoplasm Staging
-
Ovarian Neoplasms / pathology
-
Ovarian Neoplasms / therapy*
-
Ovary / surgery
-
Paclitaxel / therapeutic use
-
Polyethylene Glycols / therapeutic use
-
Quality of Life
-
Randomized Controlled Trials as Topic
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
liposomal doxorubicin
-
Deoxycytidine
-
Bevacizumab
-
Polyethylene Glycols
-
Doxorubicin
-
Carboplatin
-
Paclitaxel
-
Gemcitabine